Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
13 pending office actions • 7 art units • 12 examiners • 0 of 13 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Intellia Therapeutics Inc. has 12 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 7 distinct art units, reflecting a variety of technical focuses within the biotech sector. The company is working with 12 distinct examiners, which means every pending action is assigned to a different individual. Weihua Fan is the busiest examiner, yet manages only 1 pending office action.
This distribution of 12 actions across 12 examiners shows a lack of examiner concentration. The involvement of 7 distinct art units suggests that the company's research and development efforts are technically diverse. With the various examiners to manage, the prosecution strategy must be tailored to many different individual preferences. Weihua Fan handles 1 of the active matters. The number of examiners is higher than the 7 distinct art units involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (8%) |
| §103 only | 2 (15%) |
| Double-patenting only | 1 (8%) |
| Double-patenting + other | 2 (15%) |
| Multi-statute (no §101) | 7 (54%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HASAN, KHALEDA B | 2 | 59.4% | +49.5% |
| FAN, WEIHUA | 1 | 83.4% | +12.6% |
| TATGE, LEXUS MARC | 1 | 50.0% | +100.0% |
| ZAHORIK, AMANDA MARY | 1 | 57.8% | +49.0% |
| HEASLEY, MEGHAN CHRISTINE | 1 | 75.2% | +34.0% |
| SPENCER, ANDREA LYNNE MORRIS | 1 | 22.2% | +35.7% |
| SMALL, KATHERINE R | 1 | 68.9% | +30.7% |
| KIM, TAEYOON | 1 | 51.5% | +52.1% |
| REGA, KYLE THOMAS | 1 | 62.7% | +41.4% |
| HOLLAND, PAUL J | 1 | 57.5% | +64.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19276658 | Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA) | FAN, WEIHUA | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17836265 | Modified Guide RNAs for Gene Editing | ARIETI, RUTH SOPHIA | 30d overdue |
| 18700487 | COMPOSITIONS AND METHODS FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY | TATGE, LEXUS MARC | — |
| 18572155 | METHODS FOR IN VIVO EDITING OF A LIVER GENE | ZAHORIK, AMANDA MARY | — |
| 18339665 | Compositions and Methods for Reducing HLA-A in a Cell | SPENCER, ANDREA LYNNE MORRIS | — |
| 18339930 | Compositions and Methods for Genetically Modifying CIITA in a Cell | SMALL, KATHERINE R | — |
| 18332390 | Compositions and Methods for Reducing MHC Class II in a Cell | KIM, TAEYOON | — |
| 18332335 | Polynucleotides, Compositions, and Methods for Genome Editing Involving Deamination | REGA, KYLE THOMAS | — |
| 16651911 | FORMULATIONS | BURKHART, MICHAEL D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19630254 | Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent | HASAN, KHALEDA B | — |
| 19276658 | Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA) | FAN, WEIHUA | — |
| 18700487 | COMPOSITIONS AND METHODS FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY | TATGE, LEXUS MARC | — |
| 18572155 | METHODS FOR IN VIVO EDITING OF A LIVER GENE | ZAHORIK, AMANDA MARY | — |
| 18287227 | INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF | HEASLEY, MEGHAN CHRISTINE | — |
| 18339665 | Compositions and Methods for Reducing HLA-A in a Cell | SPENCER, ANDREA LYNNE MORRIS | — |
| 18339930 | Compositions and Methods for Genetically Modifying CIITA in a Cell | SMALL, KATHERINE R | — |
| 18332390 | Compositions and Methods for Reducing MHC Class II in a Cell | KIM, TAEYOON | — |
| Art Unit | Apps |
|---|---|
| 1636 | 3 |
| 1631 | 2 |
| 1626 | 1 |
| 1633 | 1 |
| 1656 | 1 |
| 1635 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19630254 | Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent | HASAN, KHALEDA B | 1636 | §103DP | Non-Final OA | — | Pending | Mar 26, 2026 |
| 19276658 | Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA) | FAN, WEIHUA | — | DP | Non-Final OA | — | Pending | Jul 22, 2025 |
| 18700487 | COMPOSITIONS AND METHODS FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY | TATGE, LEXUS MARC | — | §101§103§112DP | Non-Final OA | — | Pending | Apr 11, 2024 |
| 18572155 | METHODS FOR IN VIVO EDITING OF A LIVER GENE | ZAHORIK, AMANDA MARY | — | §102§103§112 | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18287227 | INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF | HEASLEY, MEGHAN CHRISTINE | 1626 | §103 | Non-Final OA | — | Pending | Oct 17, 2023 |
| 18339665 | Compositions and Methods for Reducing HLA-A in a Cell | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103§112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18339930 | Compositions and Methods for Genetically Modifying CIITA in a Cell | SMALL, KATHERINE R | 1633 | §102§112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18332390 | Compositions and Methods for Reducing MHC Class II in a Cell | KIM, TAEYOON | 1631 | §102§103§112 | Non-Final OA | — | Pending | Jun 09, 2023 |
| 18332335 | Polynucleotides, Compositions, and Methods for Genome Editing Involving Deamination | REGA, KYLE THOMAS | 1636 | §102§103§112 | Non-Final OA | — | Pending | Jun 09, 2023 |
| 17965366 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | HOLLAND, PAUL J | 1656 | §103 | Non-Final OA | — | Pending | Oct 13, 2022 |
| 17836265 | Modified Guide RNAs for Gene Editing | ARIETI, RUTH SOPHIA | 1635 | §102§103§112Other | Final Rejection | 30d overdue | Pending | Jun 09, 2022 |
| 17735929 | Methods and Compositions for Directed Genome Editing | HASAN, KHALEDA B | 1636 | §103§112DP | Non-Final OA | — | Pending | May 03, 2022 |
| 16651911 | FORMULATIONS | BURKHART, MICHAEL D | 1638 | §102§103 | Final Rejection | — | Pending | Mar 27, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial